Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies.

Patient advocacy groups had decried the firings, and lobbying groups rushed to save some slots that were in part funded by ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

Those rehired by the Trump administration include at least 10 FDA staffers responsible for reviewing the safety of new food ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Testosterone replacement therapy, also known as TRT, has surged in popularity, but there are potential risks. Here's what to know.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...